--- title: "Inhibrx Biosciences (INBX) stock: news and investor profile" url: "https://aibio.space/companies/inhibrx-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Inhibrx Biosciences, Inc. (NASDAQ: INBX), United States. The directory classifies it as Biotechnology." --- INBX Inhibrx Biosciences, Inc. NASDAQ · United States # Inhibrx Biosciences (INBX) news Debt Financing · 2026-07-16 ## [Inhibrx expands Oxford Finance facility to $500.0 million](https://aibio.space/news/inhibrx-expands-oxford-finance-facility-500-0-million/) Inhibrx's Oxford Finance facility now totals up to $500.0 million. The company funded $100.0 million at signing, and up to $225.0 million more depends on the lenders' discretion. ## Latest Inhibrx Biosciences news 1. 2026-07-16 Debt Financing [Inhibrx expands Oxford Finance credit facility to up to $500.0 million](https://aibio.space/news/inhibrx-expands-oxford-finance-credit-facility-up-500-0-million/) A second amendment adds a tranche of up to $325.0 million, of which $100.0 million was funded at signing. The lenders received warrants for 21,457 shares at $93.21 per share. 2. 2025-01-13 Debt Financing [Inhibrx Biosciences gets $100.0 million at close of Oxford Finance term loan facility](https://aibio.space/news/inhibrx-biosciences-gets-100-0-million-close-oxford-finance-term-loan/) The loan agreement allows up to $150.0 million, with the remaining $50.0 million at the lenders' sole discretion. The loan matures January 1, 2030 and comes with warrants for 140,741 shares at $14.21. Oxford Finance LLC is collateral agent. 3. 2025-01-13 Debt Financing [Inhibrx Biosciences closes Oxford Finance loan of up to $150 million, funds $100 million](https://aibio.space/news/inhibrx-biosciences-closes-oxford-finance-loan-up-150-million-funds/) The five-year facility pays interest only until March 2028. Oxford also received warrants for 140,741 shares at $14.21 per share. ## Inhibrx Biosciences at a glance - **Ticker**: INBX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $133.3 million ### Related companies - [Zivo Bioscience](https://aibio.space/companies/zivo-bioscience/) OTC: ZIVO - [Beam Therapeutics](https://aibio.space/companies/beam-therapeutics/) NASDAQ: BEAM - [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) NASDAQ: ZBIO - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX - [Passage Bio](https://aibio.space/companies/passage-bio/) NASDAQ: PASG - [PMV Pharmaceuticals](https://aibio.space/companies/pmv-pharmaceuticals/) NASDAQ: PMVP - [Mineralys Therapeutics](https://aibio.space/companies/mineralys-therapeutics/) NASDAQ: MLYS - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) NASDAQ: PVLA ### Also on NASDAQ - [Savara](https://aibio.space/companies/savara/) SVRA - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics-qncx/) QNCX - [PACIFIC BIOSCIENCES OF CALIFORNIA, INC.](https://aibio.space/companies/pacific-biosciences-of-california/) PACB - [Aura Biosciences](https://aibio.space/companies/aura-biosciences/) AURA - [PMV Pharmaceuticals](https://aibio.space/companies/pmv-pharmaceuticals/) PMVP - [NovaBridge Biosciences](https://aibio.space/companies/novabridge-biosciences/) NBP ## What Inhibrx Biosciences does Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates developed using its proprietary modular protein engineering platforms. After a May 2024 separation and merger involving its former parent and a subsidiary of Sanofi, the company continues as a stand-alone, publicly traded company focused on ozekibart (INBRX-109) and INBRX-106, both of which are clinical-stage programs. Ozekibart is a tetravalent therapeutic candidate targeting death receptor 5, or DR5, which the company says induces cancer-specific programmed cell death. It is being investigated in chondrosarcoma, Ewing sarcoma, colorectal cancer and certain other solid tumor types. In October 2025 the company announced positive data from its ozekibart registration-enabling trial in advanced or metastatic, unresectable chondrosarcoma. INBRX-106 is a hexavalent OX40 agonist being investigated in non-small cell lung cancer and head and neck squamous cell carcinoma. The company says both programs have key data or milestone events expected in 2026. Its team brings experience from organizations including Genentech, Gilead Sciences, Merck, Novartis, Pfizer and Roche. | Product or program | What it is | Stage | |---|---|---| | Ozekibart (INBRX-109) | Tetravalent DR5 agonist for chondrosarcoma and other solid tumors | Registration-enabling trial; positive data announced October 2025 | | INBRX-106 | Hexavalent OX40 agonist for non-small cell lung cancer and head and neck squamous cell carcinoma | Clinical-stage | Summarised from the company's [10-K filed Mar 19, 2026](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/inbx-20251231.htm). ## Inhibrx Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.3 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | [$200,000](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | | Research and development | [$113.0 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | [$203.7 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | | Net income (loss) | [-$140.1 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | [$1.69 billion](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | | Cash from operations | [-$129.8 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | [-$194.4 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | | Cash and equivalents | [$124.2 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000042/) | [$152.6 million](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $133.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Inhibrx Biosciences What is the ticker symbol of Inhibrx Biosciences? Inhibrx Biosciences, Inc. trades under the ticker INBX on NASDAQ. Where is Inhibrx Biosciences listed? Inhibrx Biosciences, Inc. is listed on NASDAQ. What is the SEC CIK of Inhibrx Biosciences? The SEC Central Index Key (CIK) for Inhibrx Biosciences, Inc. is 2007919. Its filings are on SEC EDGAR. How many shares does Inhibrx Biosciences have outstanding? 14,717,660 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Inhibrx Biosciences listed under? Our directory records Inhibrx Biosciences, Inc. under United States. What does Inhibrx Biosciences do? Our directory classifies Inhibrx Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Inhibrx Biosciences? The ISIN recorded for Inhibrx Biosciences, Inc. is US45720N1037. Does aibio.space cover Inhibrx Biosciences? aibio.space lists Inhibrx Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Inhibrx Biosciences incorporated? SEC records list its state or country of incorporation as DE. What does Inhibrx Biosciences develop? Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates developed using its proprietary modular protein engineering platforms. After a May 2024 separation and merger involving its former parent and a subsidiary of Sanofi, the company continues as a stand-alone, publicly traded company focused on ozekibart (INBRX-109) and INBRX-106, both of which are clinical-stage programs. What is Ozekibart (INBRX-109) from Inhibrx Biosciences? Ozekibart (INBRX-109): Tetravalent DR5 agonist for chondrosarcoma and other solid tumors Stage: Registration-enabling trial; positive data announced October 2025. What is INBRX-106 from Inhibrx Biosciences? INBRX-106: Hexavalent OX40 agonist for non-small cell lung cancer and head and neck squamous cell carcinoma Stage: Clinical-stage. What was Inhibrx Biosciences's revenue last year? $1.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Inhibrx Biosciences profitable? Inhibrx Biosciences, Inc. reported a net loss of $140.1 million for the fiscal year ended Dec 31, 2025, and used $129.8 million of cash in operations, per its annual report to the SEC. How much does Inhibrx Biosciences spend on research and development? $113.0 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Inhibrx Biosciences Members talk about Inhibrx Biosciences (INBX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Inhibrx Biosciences, newest first. Each line links the filing it comes from. 1. 2026-07-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/exhibit991-pressreleaseoxf.htm) 2. 2026-03-19 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/inbx-20251231.htm) 3. 2025-03-17 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000019/inbx-20241231.htm) 4. 2025-01-13 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000003/exhibit991-pressreleaseoxf.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INBX on TradingView](https://www.tradingview.com/symbols/NASDAQ-INBX/). ## SEC filings and registration - **SEC name**: Inhibrx Biosciences, Inc. - **CIK**: 2007919 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: INBX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037 - **Phone**: (858) 795-4220 - **Shares outstanding**: 14,717,660 as of 2026-08-07 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000050/inhibrx-20260928.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/inhibrx-20260908.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/inhibrx-20260813.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000042/inhibrx-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/inhibrx-20260715.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm) filed 2026-06-15 - [8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000030/inhibrx-20260603.htm) filed 2026-06-03 - [8-K](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/inhibrx-20260514.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002007919), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Inhibrx Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INBX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Inhibrx Biosciences, Inc. - **Ticker**: INBX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US45720N1037 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INBX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/inhibrx-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Inhibrx Biosciences (INBX) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/inhibrx-biosciences/